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Abstract 
Background: The excess risks of mortality and cardiovascular morbidity among patients with type 2 diabetes mel‑
litus (T2DM) is well known. In this nationwide study, we assessed risks of mortality and cardiovascular events compar‑
ing patients with T2DM and matched controls.
Methods: We identified patients with T2DM in a retrospective cohort study using the database of the National 
Health Insurance Fund between 1 January 2010 and 31 December, 2013. Controls were randomly included and 
matched according to age, gender, and zip code of residence. Patients were divided into subgroups according to age 
decades for outcome analyses.
Results: During the mean follow‑up period of 2.3 years, 152,678 patients with T2DM and 305,356 matched controls 
were included. Patients with T2DM showed significantly higher risk for all‑cause mortality (HR 1.26, 95% CI 1.22–1.29, 
p < 0.0001), myocardial infarction (HR 1.81, 95% CI 1.69–1.94, p < 0.0001) and stroke (HR 1.40, 95% CI 1.35–1.46, 
p < 0.0001) compared to matched controls. The higher risk associated with T2DM for mortality, myocardial infarction 
and stroke differed significantly between age groups  (pinteraction < 0.05 for all outcomes) with significantly higher risk 
observed in younger patients.
Conclusions: The risk of cardiovascular outcomes and all‑cause mortality is significantly higher in patients with 
T2DM. Notably, the relative hazard increases with decreasing age suggesting that younger patients with T2DM should 
receive more attention for cardiovascular prevention.
Keywords: Type 2 diabetes mellitus, Cardiovascular outcome, Cardiovascular morbidity, All‑cause mortality, 
Myocardial infarction, Stroke
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Cardiovascular diseases in T2DM are the leading cause 
of death, occurring with a span of typically 14.6 years [1, 
2], and the severity and the prevalence are significantly 
greater than in non-diabetic population [3]. Despite sig-
nificant improvement in diabetes care, several studies 
have painted to substantially increased mortality and 
cardiovascular morbidity in patients with T2DM [4]. In 
Ontario, Canada, and in UK, the mortality rate ratio of 
diabetes dropped from 1.90 to 1.51 and from 2.14 to 1.65, 
showing higher corresponding rate ratios in younger 
cohort [5].
In a recently published Swedish registry study, the 
risk of any cause of death was also significantly higher 
among patients with T2DM compared to controls 
(adjusted hazard ratio, HR 1.15, 95% CI 1.14–1.16). The 
Open Access
Cardiovascular Diabetology
*Correspondence:  istvan.wittmann@aok.pte.hu 
1 2nd Department of Medicine and Nephrological Center, Faculty 
of Medicine, University of Pécs, Pacsirta str. 1, Pecs 7624, Hungary
Full list of author information is available at the end of the article
Page 2 of 8Kiss et al. Cardiovasc Diabetol  (2018) 17:107 
risk of all-cause and cardiovascular death increased with 
younger age [6]. The Emerging Risk Factors Collabora-
tion reported 1.80 hazard ratio, for all-cause death in 
T2DM patients as compared to persons without it [7]. 
Norhammar assessed the risk of cardiovascular morbid-
ity in Swedish population, showing an excess risk ratio for 
myocardial infarction (1.68–1.74) and stroke (1.45–1.54) 
in the T2DM group as compared to the non-diabetic 
Swedish population [8]. A similar result was presented in 
U.S. population with a relative risk ratio for myocardial 
infarction 1.8 (1.3–2.3) and stroke 1.5 (1.1–2.0) [9].
Cardiovascular morbidity and mortality is one of the 
highest in Hungary among OECD countries. In a 2013 
report, Hungary was the second behind Slovakia in case 
of mortality rates for CVD with 598 deaths per 100.000 
populations [10].
We designed our study to explore cardiovascular mor-
bidity and mortality in the T2DM population using data 
of all patients diagnosed between 2010 and 2013 and 
compared to a control population matched by age, gen-
der and residence extracted from the database of the 
Hungarian National Health Insurance Fund. We aimed 
to explore age-dependent effects of T2DM on mortality, 
myocardial infarction and stroke in subgroups of patients 
defined by decades. The Hungarian National Health 
Insurance Fund database is a nationwide insurance sys-
tem collecting patient ID-based ICD-10 code informa-
tion from all in- and out-patient visits within primary 
and hospital care as well as from all prescription of drugs 
which are reimbursed in Hungary. In addition to collect-
ing information on diagnosis, the NHIF database also 
records treatments and all therapeutic procedures, length 
of hospital stay and the in and out of hospital all-cause 
mortality. The NHIF covers close to 100% of Hungarian 
population, however there are certain (but low level) pri-
vate care visits which are out of our investigation. Dur-
ing the investigated period, all type 2 diabetes treatments 
were reimbursed which allows us to identify T2DM 
patients.
On the other hand, NHIF database does not contain 
personalized information on laboratory test results e.g. 
 HbA1c or cholesterol level as well as does not give infor-
mation on patients’ characteristics e.g. weight and BMI.
Methods
Study design and overview
In our retrospective cohort study, cases of T2DM patients 
(n = 152,678) starting antidiabetic therapy between 1 Jan-
uary, 2010 and 31 December, 2013 were retrospectively 
extracted from the database of the National Health Insur-
ance Fund as an anonymized, aggregated patient data, 
and were considered as T2DM patients if having antidia-
betic treatment (ATC A10) but not matching previously 
detailed and published criteria for type 1, insulin depend-
ent diabetes and not having polycystic ovarium syndrome 
(ICD 10 E282) [11].
Our main goal was to investigate the risk of cardiovas-
cular morbidity and all-cause mortality since the diagno-
sis of diabetes. For this reason, we needed to identify the 
date of diagnosis of diabetes, this way only incident pop-
ulation met our criteria. Onset of diabetes was defined as 
the first occurrences of diabetes ICD code (E10–E14) in 
the database for a patient or the first antidiabetic treat-
ment, whichever occurred first. Combined records of 
ICD E10–14 and ATC A10 treatment (with the exclu-
sion of PCOS diagnosis) together with specified algo-
rithm for excluding type 1 diabetes ensures the inclusion 
of all T2DM patients in Hungary who are involved into 
national diabetes care.
The control cohort (n = 305,356) was randomly 
selected from the total population recorded in NHIF 
database by matching the age at diabetes onset, gender 
and zip code of residence with the T2DM cohort result-
ing in two controls for each DM patient, matching 1:2. 
In the case of controls no diabetes related ICD codes or 
antidiabetic treatment were recorded.
The data source included information on mortal-
ity for any causes, cardiovascular complications of dia-
betes like incidence of myocardial infarction (ICD-10 
I21–24) and ischemic and hemorrhagic stroke (ICD-10 
I61–63, G4630, G4640, G4580, G4590) in in- and out-
patient records. The International Classification of Dis-
eases (ICD) codes of 9th and 10th Revisions, were used 
to define acute myocardial infarction, stroke diagnoses 
from 1 January, 2010 onward. Dates of death were also 
retrieved from the National Health Insurance Fund data-
base, however this database does not include the cause of 
death, therefore we used only the cases of death from any 
type of causes (all-cause mortality) in our analysis.
All-cause mortality and cardiovascular morbidity as 
myocardial infarction and stroke were assessed in a 
period of 58 months, from 1 January, 2010 till 31 Octo-
ber, 2014, by comparing T2DM with the matched control 
population. In both T2DM and control patients, sub-
groups were defined according to decades of age result-
ing in subgroups of > 70, 61–70, 51–60, 41–50, 31–40 and 
< 31. Patients were also evaluated according to gender.
Limitation of the NHIF data investigation is that allows 
only detection of use of reimbursed drugs. Statin therapy 
during the investigated period was reimbursed, but blood 
pressure lowering and antiplatelet therapies are not com-
pletely reimbursed in Hungary, consequently these infor-
mation do not exist in the NHIF database.
This study was approved by the Regional Research 
Ethics Committee of the Medical Center, University of 
Pécs, Medical School, Hungary (Study License Number: 
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6962/2017) and run without commercial sponsorship. 
The study protocol was also reviewed and confirmed by 
the National Health Insurance Fund (NHIF) (Identifica-
tion Number: S04/161/2016).
Statistical analysis
Survival analyses were performed by Cox regression and 
age and gender matched groups were used. Our model 
runs separately for the sexes and the individual age 
groups, consequently the proportionality criterion for 
cox does not deteriorate if the same parentage is not the 
same for different gender or age groups). The final result 
was the adequately weighted average of the results in the 
different groups. This approach ensured correction for 
gender and age group. As the risk of death was higher in 
the first 4 months after the diagnosis of diabetes, and the 
risk of stroke and myocardial infarction was also higher 
in the 1st  month, time dependent factor was used to 
separate this short-term effect from the long-term effect. 
Simultaneous confidence intervals including ratio of haz-
ard ratios were calculated using contrast matrix.
Mean of age and follow-up time were compared using 
Welch’s two-sample test. Proportion of statin treatment, 
prior stroke and myocardial infarction were compared 
using Chi square test.
All analyses were performed by using of R Software, 
version 3.4.2 (2017-09-28), applying survival, survminer 
and multcomp packages [12].
Results
Study population
Between 1 January, 2010 and 31 December, 2013, 152,678 
patients with T2DM and 305,356 matched controls were 
selected for further analyses. Baseline characteristics 
of T2DM patients and control subjects are presented in 
Table  1. Among T2DM patients, 51.89% were female. 
Mean age at diagnosis was 59.43, 3 years lower in males 
compared to female patients. Mean follow-up period 
of the study was 2.32 years in T2DM and 2.4 in control 
group.
Mortality and cardiovascular events
Overall, 13,413 (8.8%) of the 152,678 patients with dia-
betes died during the study period, as compared with 
20,154 (6.6%) patients of 305,356 controls. In Cox regres-
sion analyses, hazard ratio (HR) for all-cause mortality 
was 1.26 (95% CI 1.22–1.29 p < 0.0001) showing a signifi-
cantly higher risk for all-cause death in T2DM (Fig. 1a). 
Within the first 4 months of diagnosis, an even larger risk 
increase was found (HR for the first 4 months: 2.16, 95% 
CI 2.02–2.30, p < 0.0001).
Patients with T2DM showed a significantly higher risk 
for myocardial infarction [3330 (2.2%) vs. 2442 (0.8%) 
events; HR 1.81, 95% CI 1.69–1.94, p < 0.0001] (Fig.  1b) 
and stroke [8502 (5.6%) vs. 9475 (3.1%) events; HR 1.40, 
95% CI 1.35–1.46, p < 0.0001] (Fig.  1c) compared to 
matched control patients. In cases of both cardiovascular 
complications, differences in HR-s were also significantly 
larger in the 1st month (HR for MI 20.19, 95% CI 16.43–
24.80; p < 0.0001 and for stroke 6.52, 95% CI 5.97–7.11; 
p < 0.0001).
Age‑dependent analyses
The relative risks of T2DM vs. matched controls regard-
ing all outcomes were evaluated in pre-defined age sub-
groups (Fig. 2). Regarding mortality, a significant excess 
of risk associated with T2DM was present in all sub-
groups except for the smallest group of patients aged 
19–30 years, presumably due to low sample size. Interac-
tion testing showed a significant interaction of age with 
the risk of T2DM  (pinteraction = 0.01). Interaction testing 
in age-defined subgroups for myocardial infarction and 
stroke provided similar findings (Fig. 2).
Gender differences
Among patients with T2DM, 52% were male and 48% 
were female. Men and women with T2DM had similar 
mortality (9.2% vs. 8.5%), myocardial infarction (2.8% 
vs. 1.6%) and stroke (5.7% vs. 5.5%). In both genders, we 
observed a significantly higher risk for mortality (HR 
1.17 and 1.37), myocardial infarction and stroke in case 
of T2DM compared to matched controls (Fig. 3). Based 
on the results of interaction testing, the risk of T2DM for 
mortality and stroke was larger in female patients than 
in male, while no gender-related difference was found in 
myocardial infarction (Fig. 3).
Discussion
The main findings of the current large-scale, nationwide 
study can be summarized as follows:
1. Patients with T2DM have a significantly higher risk 
for myocardial infarction, stroke and mortality. This 
Table 1 Patient characteristics at baseline
T2DM Control p value
Population (n) 152,678 305,356
Age (years) 59.43 (59.4–59.5) 59.43 (59.3–59.4) 1
Female‑no. (%) 79,238 (51.9) 158,476 (51.9) 1
Age (years—95% CI) 60.89 (60.8–61.0) 60.89 (60.8–61.0) 1
Male—no. (%) 73,440 (48.1) 146,880 (48.1) 1
Age (years—95% CI) 57.9 (57.8–57.9) 57.9 (57.8–57.9) 1
Year of diagnosis (range) 2010–2013 2010–2013
Mean follow‑up 
(year—95% CI)
2.3 (2.3–2.3) 2.4 (2.4–2.4) < 0.0001
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excess risk depends on the age of patients with sig-
nificantly larger increase of relative risk observed in 
younger subjects than in the elderly.
2. Cardiovascular events and mortality were higher in 
both genders with T2DM, however; the risk of stroke 
and mortality was higher in female patients com-
pared to males. Myocardial infarction did not show 
gender-related differences.
Age related differences
The excess risk for cardiovascular events in patients with 
T2DM is well described in literature [2, 3, 13]. Similarly, 
prior reports suggested an age-dependent elevation of 
risk associated with T2DM [1]. In the Tancredi study, the 
authors provided a detailed analysis on the background 
of higher mortality rate in younger T2DM population [6]. 
They explained the higher mortality of younger patients 
by the higher rate of smoking (38% vs. 24% control) and 
significantly higher incidence of obesity (56% vs. 14%).
In our earlier paper, we found age-related differences 
in statin medication adherence in Hungary, where the 
younger cohort presented significantly lower, 7.9–11.8% 
adherence during 12  months, while rates of adherence 
were 15.9–23.5% in older cohorts. This feature may be 
one of the many that contribute to the higher cardiovas-
cular risk profile of younger Hungarians [14], because the 
correlation between the use of statins and improvement 
of survival is well-known especially in younger age [15].
Comparisons of mortality data
In our nationwide study, all-cause mortality was 37.89 
per 10,000 person-years between 2010 and 2013, which 
is comparable with data presented by Tancredi from a 
Swedish diabetes registry [6] with 38.64 per 10,000 per-
son-years. We found a similar incidence of mortality in 
the control group as well with 30.30 vs. 28.45 in Swed-
ish versus Hungarian patients per 10,000 person-years 
in non-diabetic populations. Norhammar investigated 
the same Swedish T2DM population presenting data for 
period between 2010 and 2013, when the mortality ratio 
varied similarly between 1.29 and 1.27, versus the non-
diabetic population [8]; a finding similar to our results.
Comparisons of cardiovascular morbidity data
Notably, the highest relative risk increase was found in 
case of myocardial infarction (HR 1.81). Data from the 
Swedish registry by Norhammar related to the same time 
period seems to be of similar effect size for myocardial 
infarction to our findings (between 1.71 and 1.68) [8]. 
Gregg also published a comparable risk elevation for the 
coronary events in 2010, with relative risk of 1.8 compar-
ing T2DM population to a non-diabetic population [9].
The hazard ratio in T2DM for stroke in Hungary was 
also comparable to the Swedish and US data detailed 
earlier. While Gregg reported a 50% risk increase in 
stroke in 2010, Norhammar measured hazard ratios of 
1.47–1.45 between 2010 and 2013. Our nationwide sur-
vey showed a 1.40 hazard ratio. In a paper using the same 
NHIF database of the year 2008, Szőcs et  al. reported a 
43.3 incidence per 10,000 in a non-selected, non-diabetic 
population for stroke in Hungary [16].
Cardiovascular complications in T2DM patients have 
significant impact on the outcome leading to higher 
resource utilization in younger patients with CVD [17]. 
High risks for cardiovascular events in our study high-
lights the need of better treatment, particularly for 
younger diabetic patients. Achievement of therapeu-
tic target in a secondary prevention of MI, or stroke in 
T2DM patients was reported to be low in an Austrian-
German multicenter analysis [18], and another study 
confirmed these findings [19].
Several recent studies reported significant improve-
ment in cardiovascular morbidity and mortality out-
comes using new options of treatment strategies in the 
secondary prevention, as e.g. the EMPA-REG OUT-
COME [20] and the CANVAS study [21], which proved 
the benefits of SGLT-2 inhibitors. However, a cardio-
vascular neutrality was verified in the trials using DPP4-
inhibitor therapies [22, 23].
Retrospective cohort based study represented a benefi-
cial change of risks in a robust study, where a decreased 
risk of cardiovascular complications was detected dia-
betic patients in Korean during the 2006–2013 study 
period [24].
Some authors hypothesize further improvement in 
the goal attainment and this way better achievements 
in the cardiovascular prevention [18], but others sug-
gest cautiousness with potential overtreatment and its 
consequences [25] relating to the increased risk of hypo-
glycemia related cardiovascular disease [26]. However, 
benefit of the intensified intervention could be supposed 
in the prevention of cerebrovascular diseases in T2DM 
patients [25] and carotid and lower extremity ultrasound 
examination may further improve the identification of 
cardiovascular risk [27].
Fig. 1 a Kaplan–Meier all‑cause mortality free survival curve comparing T2DM with matched control; b Kaplan–Meier myocardial infarction free 
survival curve comparing T2DM with matched control; c Kaplan–Meier stroke free survival curve comparing T2DM with matched control
(See figure on next page.)
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Gender differences
When assessing mortality and cardiovascular morbidity 
according to genders, we found a slightly increased mor-
tality risk for males in the T2DM population. However, if 
we compare the T2DM groups to the matched controls, 
both genders show a higher risk in T2DM than controls, 
with a significantly higher relative risk for stroke and 
mortality observed in females. This is in line with gen-
eral observations, which suggest that T2DM increases the 
risks (especially postmenopausal) of females more than 
that of males [28], and treatment for women with diabetes 
was recommended to be more aggressive to that of men.
Fig. 2 Adjusted hazard ratios for all‑cause mortality, myocardial infarction and stroke according age cohorts comparing T2DM with matched 
control. Age‑dependent interactions: mortality:  pinteraction = 0.01, myocardial infarction:  pinteraction = 0.003 and stroke:  pinteraction < 0.0001
Fig. 3 Adjusted hazard ratios for all‑cause mortality, myocardial infarction and stroke according male and female within T2DM and Control 
population
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Backgrounds of cardiovascular events
Though we do not have data for direct comparison, we 
found a relatively early diabetes onset in Hungary com-
paring to other Western countries, recording 59  year as 
a mean age at the diagnosis of T2DM (57 years for males 
and 60 for females). While similar cohort studies showed 
a diabetes onset over 65 years, such as the Swedish diabe-
tes registry present 65 mean years between 1998 and 2011. 
This difference may be attributed to the higher incidence of 
risk factors for diabetes in Hungary. In the OECD obesity 
report [29], Hungary is among the top countries having the 
highest incidence rate for obesity. This survey reported a 
30% incidence rate for our country in 2015, while Sweden 
was among countries at the lower end, recording 12.3% of 
the population reaching the criteria of obesity. Regarding 
obesity and related metabolic syndrome there is no addi-
tive risk for cardiovascular morbidity in case of the syn-
drome compared to the single components of it [30].
Early events
The probability of myocardial infarction and stroke cases 
and consequently incidence of all-cause mortality was 
higher shortly after diabetes diagnosis. This result may 
come due to late diagnosis of diabetes at certain patients, 
which means, most of these patients missed the primary 
prevention systems in primary care and appeared in 
NHIF with diabetes after myocardial infarction or stroke 
and/or consequent mortality. This result highlights the 
need of better primary prevention care strategies in 
Hungary.
Strengths and limitations
Our analysis has strengths and weaknesses, as well. 
The sample size of the patient group, the high number 
of events, and the long follow-up provided sufficient 
power for the analyses. The limitation of the study is 
that it includes patients treated by antidiabetic agents 
only, and not involved diabetics on life style modifica-
tion. Further weakness of our trial is that we were not 
able to get data about hemoglobin  A1c, cholesterol level, 
and cause of death as well as we could not record more 
detailed risk factors and we did not have option to 
evaluate the impact of obesity. Moreover, in our study, 
HR-analyses are not fully adjusted for all known cardio-
vascular risk factors, and with the given investigation 
period, we evaluated incident patients with (on aver-
age) 2.3 years of follow up, only.
Conclusions
T2DM patients in Hungary showed a significantly 
higher risk for stroke, myocardial infarction and mor-
tality. The excess risk associated with T2DM increased 
by decreasing age of the evaluated group of patient 
group suggesting an important age-dependent interac-
tion. More efforts should be focused on the younger 
population to improve the prevention of cardiovascular 
events.
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